Nutritional issues in patients with obesity and cirrhosis.

Luigi Schiavo, Luca Busetto, Manuela Cesaretti, Shira Zelber-Sagi, Liat Deutsch, Antonio Iannelli

Journal: World journal of gastroenterology 2018;24(30):3330-3346

PMID: 30122874

Plain Language Summary

plain language summary logo

Non-alcoholic fatty liver disease (NAFLD) occurs when fats accumulate in the liver in the absence of excess alcohol intake and if unmanaged can advance to severe liver disease known as cirrhosis. NAFLD and cirrhosis can be associated with obesity, muscle wastage and nutrient deficiencies. This review of 165 papers aimed to discuss muscle wastage and nutrient deficiencies in patients with obesity and cirrhosis with a view to making supplementation recommendations. The authors first discussed that the risk of muscle wastage in patients with obesity and cirrhosis is high and when combined with obesity may affect other chronic diseases and impact the progression of NAFLD to cirrhosis. The paper then discusses that vitamin and mineral deficiencies are common in patients with cirrhosis possibly due to reduced intake, poor absorption and the reduction of carrier protein production in the liver. Deficiencies in vitamins D and E and zinc and magnesium were extensively featured. Protein and calorie intake were also reviewed and although weight loss should be encouraged in patients with obesity and cirrhosis, over-restriction could exacerbate muscle breakdown. Any low-calorie diets should contain adequate protein content. Bariatric surgery, in patients with obesity and cirrhosis needs to be performed on a case-by-case basis involving many different medical disciplines. It was concluded that obesity and cirrhosis are commonly occurring simultaneously and poses a management challenge for medical professionals. This paper could be used by health care professionals to understand the possible nutritional deficiencies that need to be monitored in patients with obesity and cirrhosis and where bariatric surgery may be indicated.

Abstract

Obesity and metabolic syndrome are considered as responsible for a condition known as the non-alcoholic fatty liver disease that goes from simple accumulation of triglycerides to hepatic inflammation and may progress to cirrhosis. Patients with obesity also have an increased risk of primary liver malignancies and increased body mass index is a predictor of decompensation of liver cirrhosis. Sarcopenic obesity confers a risk of physical impairment and disability that is significantly higher than the risk induced by each of the two conditions alone as it has been shown to be an independent risk factor for chronic liver disease in patients with obesity and a prognostic negative marker for the evolution of liver cirrhosis and the results of liver transplantation. Cirrhotic patients with obesity are at high risk for depletion of various fat-soluble, water-soluble vitamins and trace elements and should be supplemented appropriately. Diet, physical activity and protein intake should be carefully monitored in these fragile patients according to recent recommendations. Bariatric surgery is sporadically used in patients with morbid obesity and cirrhosis also in the setting of liver transplantation. The risk of sarcopenia, micronutrient status, and the recommended supplementation in patients with obesity and cirrhosis are discussed in this review. Furthermore, the indications and contraindications of bariatric surgery-induced weight loss in the cirrhotic patient with obesity are discussed.

Address: Department of Translational Medical Science, University of Campania "Luigi Vanvitelli", Naples 80131, Italy.; Department of Medicine, University of Padua, Padua 35128, Italy.; Department of HPB Surgery and Liver Transplantation, Hôpital Beaujon, AP-HP, Clichy 92110, France.; School of Public Health, University of Haifa, Haifa 3498838, Israel.; Department of Gastroenterology and Liver disease, Tel Aviv Medical Center, 62431, Tel-Aviv 62431, Israel.; Digestive Unit, Archet 2 Hospital, University Hospital of Nice, F-06202, Nice, France; Inserm, U1065, Team 8 "Hepatic complications of obesity", Nice F-06204, France.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.